Veradermics holds $798.4m as its hair-loss tablet reports positive male trial results

Veradermics, Inc ended the third quarter of 2026 with $798.4 million in cash and securities, a position the company says is enough to fund operations until 2030. It reported a quarterly net loss of $21.0 million. The figures came in its results update on 10 November.

The company also said two studies of VDPHL01, its extended-release oral minoxidil tablet for pattern hair loss, were positive in men. These were the Phase 3 Study 304 and the 12-month Phase 2/3 Study 302. Veradermics said neither study produced serious adverse events judged related to treatment, nor any cardiac events that were specifically flagged for monitoring.

The summary of the update gives no efficacy numbers, dosing information or timetable for regulatory filings, so the size of the benefit and the route to market cannot yet be judged. For context, oral minoxidil is an established compound, and the cardiovascular profile of any oral formulation is a natural focus for prescribers and regulators. That makes the safety statement notable, though it is not a substitute for the full dataset.

The next disclosed milestone is topline data from Study 306, which enrolled women, expected in the first half of 2027.